Journal of Neuro-Oncology

, Volume 111, Issue 2, pp 163–167 | Cite as

Frequency of brain metastases from prostate cancer: an 18-year single-institution experience

  • Orazio Caffo
  • Antonello Veccia
  • Gianni Fellin
  • Salvatore Mussari
  • Lucianna Russo
  • Luigi Tomio
  • Enzo Galligioni
Clinical Study

Abstract

It has recently been reported that the incidence of brain metastases (BMs) from prostate cancer (PC) has increased in comparison with historical series. The aim of this study was to compare the incidence of BMs in the pre- and post-docetaxel era in a single institution in which all oncological patients are referred to one Radiotherapy and one Medical Oncology Department. We searched the electronic databases of these departments for all males with BMs entered from 1994 to 2011. The year of the introduction of docetaxel into clinical practice (2002) divided the observation period into two 9-year periods: period 1 (P1) from 1994 until 2002 (P1), and period 2 (P2) after 2002. The number of patients with BMs was constant: 241 patients in P1 and 249 in P2. The greatest changes in frequency between P1 and P2 involved colorectal cancer (+75.9 %), renal cancer (+141.9 %), and PC (+238.7 %). The total number of patients with BMs from PC was nine: two in P1 (0.8 %) and seven in P2 (2.8 %). All but two of these patients developed BMs after becoming castration-resistant. Median BM-free survival was 36 months, whereas median BM survival was 8 weeks. As the appearance of BMs in the natural history of PC is usually related to the late phase of the disease, and mortality due to PC remained constant, it seems that there really has been an increase in the frequency of BMs from PC that may reflect a gain in survival.

Keywords

Prostate cancer Brain metastases Docetaxel Cabazitaxel 

References

  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781PubMedCrossRefGoogle Scholar
  3. 3.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRefGoogle Scholar
  4. 4.
    Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520PubMedCrossRefGoogle Scholar
  5. 5.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154PubMedCrossRefGoogle Scholar
  6. 6.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005PubMedCrossRefGoogle Scholar
  7. 7.
    Caffo O, Gernone A, Ortega C, Sava T, Carteni G, Facchini G, Re GL, Amadio P, Bortolus R, Pagliarulo V, Prati V, Veccia A, Galligioni E (2012) Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol 107:191–196PubMedCrossRefGoogle Scholar
  8. 8.
    McCutcheon IE, Eng DY, Logothetis CJ (1999) Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86:2301–2311PubMedCrossRefGoogle Scholar
  9. 9.
    Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK (2003) Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer 98:363–368Google Scholar
  10. 10.
    Galligioni E, Berloffa F, Caffo O, Tonazzolli G, Ambrosini G, Valduga F, Eccher C, Ferro A, Forti S (2009) Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years’ experience. Ann Oncol 20:349–352PubMedCrossRefGoogle Scholar
  11. 11.
    Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14PubMedCrossRefGoogle Scholar
  12. 12.
    Smedby KE, Brandt L, Backlund ML, Blomqvist P (2009) Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101:1919–1924PubMedCrossRefGoogle Scholar
  13. 13.
    Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRefGoogle Scholar
  14. 14.
    Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska-Mielcarek K, Karpinska A, Staroslawska E, Kubiatowski T, Szczylik C (2009) Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 117:297–303PubMedCrossRefGoogle Scholar
  15. 15.
    Shao YY, Lu LC, Cheng AL, Hsu CH (2011) Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. Oncologist 16:82–86PubMedCrossRefGoogle Scholar
  16. 16.
    Mongan JP, Fadul CE, Cole BF, Zaki BI, Suriawinata AA, Ripple GH, Tosteson TD, Pipas JM (2009) Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 8:100–105CrossRefGoogle Scholar
  17. 17.
    Martel CL, Gumerlock PH, Meyers FJ, Lara PN (2003) Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29:171–187PubMedCrossRefGoogle Scholar
  18. 18.
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245PubMedCrossRefGoogle Scholar
  19. 19.
    Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM (2009) What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 103:1641–1646PubMedCrossRefGoogle Scholar
  20. 20.
    Sartor AO, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, de Bono JS (2011) Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J Clin Oncol 29 (suppl):abs 4525Google Scholar
  21. 21.
    Goodman O, Chi KN, Molina A, Logothetis C, Jones RJ, Staffurth J, North SA, Vogelzang NJ, Saad F, Mainwaring P, Harland SJ, Li J, Kheoh T, Hagg C, Scher HI, Fizazi K (2012) Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30 (suppl):abs 4558Google Scholar
  22. 22.
    Deeken JF, Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663–1674PubMedCrossRefGoogle Scholar
  23. 23.
    van Brussel JP, Mickisch GH (2003) Multidrug resistance in prostate cancer. Onkologie 26:175–181PubMedCrossRefGoogle Scholar
  24. 24.
    Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM (2003) Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138:1367–1375PubMedCrossRefGoogle Scholar
  25. 25.
    Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422PubMedCrossRefGoogle Scholar
  26. 26.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Orazio Caffo
    • 1
  • Antonello Veccia
    • 1
  • Gianni Fellin
    • 2
  • Salvatore Mussari
    • 2
  • Lucianna Russo
    • 1
  • Luigi Tomio
    • 2
  • Enzo Galligioni
    • 1
  1. 1.Medical Oncology DepartmentSanta Chiara HospitalTrentoItaly
  2. 2.Radiotherapy DepartmentSanta Chiara HospitalTrentoItaly

Personalised recommendations